Medeikon Announces New Associate Director of Software Development
Posted on: Wednesday, 22 February 2006, 12:01 CST
Expanded Software Development Staff Positions Company for Advances in Diagnosis and Treatment of Cardiovascular Disease.
Dr. Zhenyu Wu, joined Medeikon as Associate Director of Software Development. Dr. Wu will be responsible for designing and developing a software subsystem for the XploraPD Console(TM). This system is designed to meet the specific needs of cardiologists through more powerful diagnostic capabilities that allow for advanced quantification to make faster and more specific treatment decisions.
Medeikon Corporation provides medical devices for physician diagnosis and treatment of cardiovascular disease. Our initial emphasis is on vulnerable plaque, the leading cause of sudden cardiac death. Medeikon's XploraPD(TM) system distinguishes these rupture-prone lesions from other types of coronary artery tissue using optical technologies. This allows physicians make early and accurate diagnosis and then treat the condition with tools consistent with current cardiac catheterization techniques and equipment. "I am very excited about joining Medeikon. They are on the forefront of a technological breakthrough in cardiovascular disease." Dr. Wu notes. "They are moving quickly towards assisting physicians in diagnosing and treating rupture-prone plaque," states Wu.
Dr. Wu has extensive expertise in Medical Imaging, Computer Vision, Digital Video and Biometrics. Most recently, Wu served as the managing partner of MY EZ Communications, LLC, a small consulting firm developing advanced digital video solutions for law enforcement. Prior to that, Wu was involved in developing a revolutionary database management systems at RTI, serving as the technical lead in the query engine group. His extensive R&D experience also includes tenures with Siemens Corporate Research, Lockheed Martin Labs and IBM Research.
Medeikon is currently developing its technology and will license it to medical device manufacturers, pharmaceutical companies and other technology companies. Medeikon is a privately held company. Medeikon is currently engaged in a private placement for Round B financing, $15 million, through Janney Montgomery Scott LLC.
Source: Business Wire
Related Articles
- AngioScore Launches New Longer and Larger AngioSculpt(R) Devices for Treatment of Peripheral Artery Disease
- QuantRx Announces Expansion of Its Molecular Imaging Technology Platform for Development of Diagnosis and Treatment Agents for Alzheimer's Disease (AD)
- State Gives Cleveland Clinic and Fairfax Renaissance Development Corporation $60 Million To Develop Global Cardiovascular Innovation Center
- CardioVascular BioTherapeutics Initiates Study on the Treatment of Peripheral Artery Disease
- Newly Published Guidelines for Treatment of Heart Valve Disease Lower Recommended Age for Tissue Valve Recipients
- AVI BioPharma and Cook Group Enter Into License Agreement to Develop NEUGENE Drugs for Vascular Diseases
- An Open-Label Evaluation of Rifaximin in the Treatment of Active Crohn's Disease*
- The Role of Autoimmunity at Diagnosis of Type 1 Diabetes in the Development of Thyroid and Celiac Disease and Microvascular Complications
- CVBT Announces Cardio Vascu-Grow Appears to Be Safe and Well Tolerated As a Treatment for Coronary Heart Disease
- Treatment of De Quervain Disease With Triamcinolone Injection With or Without Nimesulide: a Randomized, Double-Blind, Placebo- Controlled Trial
 |
 |
User Comments (0)
RSS Feeds